Vyjuvek
Novartis’ Cosentyx gets positive CHMP opinion for polymyalgia rheumatica
If approved, this would be the first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica
AbbVie’s Rinvoq approved by European Commission for non-segmental vitiligo
Rinvoq is the first and only systemic medication approved in the EU for NSV
EMA recommends granting marketing authorisation approval for Nezglyal
The treatment is for cerebral adrenoleukodystrophy, a rare neurodegenerative disease
AstraZeneca’s Trixeo recommended by CHMP for approval in EU for asthma
Asthma affects over 360 million people worldwide, including over 40 million people in Europe
CSL’s Privigen approved as measles treatment by European Commission
Cases of measles have been rising in Europe since 2023
AstraZeneca’s Imfinzi regimen receives positive CHMP opinion for early gastric and gastroesophageal cancer
Gastric cancer is the fifth highest cause of cancer deaths worldwide, with almost a million people diagnosed annually
Sanofi’s Rezurock receives positive CHMP opinion for chronic graft-versus-host disease
Up to 50% of allogeneic haematopoietic stem cell transplant patients develop chronic GVHD
Lilly’s early Alzheimer’s disease treatment approved in the EU
Marketing authorisation follows positive late-stage trial results
Roche’s Lunsumio receives positive CHMP opinion for follicular lymphoma
The recommendation for the subcutaneous formulation follows encouraging trial data
CHMP recommends BeOne Medicines’ Tevimbra for new lung cancer indication
Non-small cell lung cancer accounts for up to 90% of all lung cancer cases
Sanofi’s Sarclisa approved by EC to treat newly diagnosed multiple myeloma
The drug is already approved in the EU across three other multiple myeloma indications
Eli Lilly’s Alzheimer’s disease drug donanemab recommended by CHMP
Up to 6.9 million people in Europe are affected by the neurodegenerative disorder